Smoking cessation therapy with varenicline

Citations Over TimeTop 18% of 2008 papers

Abstract

Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation. In this article, we discuss presently available options for smoking cessation and review the literature on efficacy of varenicline.

Related Papers

• → Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century(2009)356 cited
• → Smoking cessation and COPD(2013)182 cited
• → Characteristics of COPD Smokers and Effectiveness and Safety of Smoking Cessation Medications(2012)48 cited
• → Smoking cessation and vaccination(2023)15 cited
• → Similar quit rates are found with three smoking cessation options(2016)